Literature DB >> 8239626

Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis.

O H Gilja1, A Halstensen, A Digranes, H Mylvaganam, A Aksnes, E A Høiby.   

Abstract

After an outbreak of three cases of serogroup B meningococcal disease at a Norwegian college, 84 of 392 (21%) subjects were tonsillopharyngeal carriers of Neisseria meningitidis. To eradicate meningococcal carriage, 80 volunteers received a single dose of 400 mg of ofloxacin. Three days after treatment, all 75 evaluable volunteers were culture negative for N. meningitidis, and after 7 days none carried the strain that they carried initially, as judged by DNA fingerprinting. A single dose of ofloxacin was found to be 97.2% effective in eradicating carriage of N. meningitidis for a period of 33 days. The carriage acquisition rate among treated students was four times higher than that among nontreated noncarriers (P = 0.02). After ofloxacin treatment, no case of meningococcal disease occurred for 6 months. Ofloxacin may thus prevent the outbreak and spread of meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239626      PMCID: PMC188115          DOI: 10.1128/AAC.37.9.2024

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Preventing secondary cases of meningococcal disease by identifying and eradicating disease-causing strains in close contacts of patients.

Authors:  B E Kristiansen; Y Tveten; E Ask; T Reiten; A B Knapskog; J Steen-Johnsen; G Hopen
Journal:  Scand J Infect Dis       Date:  1992

2.  The epidemiology of meningococcal disease in Norway 1975-91.

Authors:  A Lystad; S Aasen
Journal:  NIPH Ann       Date:  1991-12

3.  Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis.

Authors:  M P Pugsley; D L Dworzack; E A Horowitz; T A Cuevas; W E Sanders; C C Sanders
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

Review 4.  The chemoprophylaxis of meningococcal infection.

Authors:  R A Wall
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

5.  Adverse effects of two rifampicin dosage regimens for the prevention of meningococcal infection.

Authors:  J D Band; D W Fraser
Journal:  Lancet       Date:  1984-01-14       Impact factor: 79.321

6.  Applications of restriction endonuclease fingerprinting of chromosomal DNA of Neisseria meningitidis.

Authors:  B Bjorvatn; V Lund; B E Kristiansen; L Korsnes; O Spanne; B Lindqvist
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

7.  The effect of rifampin on the nasopharyngeal carriage of Neisseria meningitidis in a military population.

Authors:  W E Beam; N R Newberg; L F Devine; W E Pierce; J A Davies
Journal:  J Infect Dis       Date:  1971-07       Impact factor: 5.226

8.  Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland.

Authors:  O V Renkonen; A Sivonen; R Visakorpi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

9.  Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis.

Authors:  P N Gaunt; B E Lambert
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

10.  Differentiation of B15 strains of Neisseria meningitidis by DNA restriction endonuclease fingerprinting.

Authors:  B E Kristiansen; B Bjorvatn; V Lund; B Lindqvist; E Holten
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

View more
  9 in total

Review 1.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Secondary prevention of meningococcal disease.

Authors:  B E Kristiansen; A B Knapskog
Journal:  BMJ       Date:  1996-03-09

3.  Single dose ofloxacin in the eradication of pharyngeal carriage of Neisseria meningitidis.

Authors:  A Halstensen; O H Gilja; A Digranes; H Mylvaganam; A Aksnes; E A Høiby; T Rolstad
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Fluoroquinolones in paediatrics.

Authors:  D Gendrel; F Moulin
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials.

Authors:  A Fraser; A Gafter-Gvili; M Paul; L Leibovici
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

6.  Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae.

Authors:  Patricia L Winokur; Kathryn Chaloner; Gary V Doern; Jennifer Ferreira; Michael A Apicella
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

Review 7.  Fluoroquinolones in paediatrics--1995.

Authors:  R Dagan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.

Authors:  E Wedege; J Kolberg; A Delvig; E A Høiby; E Holten; E Rosenqvist; D A Caugant
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

Review 9.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.